Clinical trial · Observational
Dual-tracer PET Radiomics for Prostate Cancer Stratification
Dual-tracer PET/CT Interpretable Radiomics for Pathological Classification and Prognostic Stratification of Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This single-center retrospective study aims to develop an interpretable radiomics model based on dual-tracer PET/CT to preoperatively predict the postoperative pathological Gleason grade group in treatment-naïve prostate cancer patients. A machine learning-based three-class prediction model will be constructed and interpreted using SHAP. Its performance will be compared with systematic biopsy results, assessing grading accuracy and prognostic value for biochemical recurrence-free survival.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biochemical Recurrence | — | UNRESOLVED | — |
| Gleason Score | — | UNRESOLVED | — |
| PET/CT | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Radiomics | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT with Gallium-68 labeled PSMA and RM26 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Retrospective Cohort
- description
- Treatment-naïve prostate cancer patients undergoing dual-tracer PET/CT before radical prostatectomy.
- interventionNames
- Diagnostic Test: PET/CT with Gallium-68 labeled PSMA and RM26
Primary outcomes (1)
- measure
- Gleason Grade Group
- timeFrame
- 2020.1 --- 2023.1
- description
- Gleason Grade Group
Secondary outcomes (1)
- measure
- Biochemical recurrence-free survival
- timeFrame
- From surgery to biochemical recurrence or study cutoff (up to 5 years)
- description
- Time from surgery to biochemical recurrence (PSA ≥ 0.2 ng/ml or initiation of salvage treatment) or last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Treatment-naïve prostate cancer with subsequent radical prostatectomy (RP) * Availability of presurgical dual-tracer PET/CT images, biopsy, and RP pathology data Exclusion Criteria: * Unavailability of imaging or pathological data * PET/CT performed after any prostate cancer-related treatment * Interval between PET and biopsy \> 3 months * Interval between biopsy and RP \> 1 month
References
Publications (0)
Data not yet available